{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:59:45Z","timestamp":1790841585368,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Rhythm Pharmaceuticals, Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03741-x","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:28:18Z","timestamp":1790839698000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Measuring Hunger Severity in Rare MC4R Pathway Diseases: Development and Psychometric Evaluation of the Most Hunger Item"],"prefix":"10.1007","author":[{"given":"Karine","family":"Cl\u00e9ment","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian L.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"K\u00fchnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M.","family":"Haqq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usha G.","family":"Mallya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2546-8980","authenticated-orcid":false,"given":"Claire","family":"Ervin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Norcross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Bhargava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Argente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"issue":"7","key":"3741_CR1","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1210\/jc.2018-00258","volume":"103","author":"KL Ayers","year":"2018","unstructured":"Ayers KL, Glicksberg BS, Garfield AS, et al. Melanocortin\u00a04 receptor pathway dysfunction in obesity: patient stratification aimed at MC4R agonist treatment. J Clin Endocrinol Metab. 2018;103(7):2601\u201312. https:\/\/doi.org\/10.1210\/jc.2018-00258.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"3741_CR2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s11154-025-09984-3","volume":"26","author":"J Argente","year":"2025","unstructured":"Argente J, Cl\u00e9ment K, Duis J, et al. Hyperphagia in rare melanocortin-4 receptor pathway diseases: therapeutic options and assessing treatment response. Rev Endocr Metab Disord. 2025;26(6):917\u201335. https:\/\/doi.org\/10.1007\/s11154-025-09984-3.","journal-title":"Rev Endocr Metab Disord"},{"issue":"S1","key":"3741_CR3","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1002\/oby.20646","volume":"22","author":"SB Heymsfield","year":"2014","unstructured":"Heymsfield SB, Avena NM, Baier L, et al. Hyperphagia: current concepts and future directions proceedings of the 2nd international conference on hyperphagia. Obesity. 2014;22(S1):S1\u201317. https:\/\/doi.org\/10.1002\/oby.20646.","journal-title":"Obesity"},{"issue":"7","key":"3741_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13915","volume":"26","author":"PL Beales","year":"2025","unstructured":"Beales PL, Cetiner M, Haqq AM, et al. Hyperphagia in Bardet\u2013Biedl syndrome: pathophysiology, burden, and management. Obes Rev. 2025;26(7):e13915. https:\/\/doi.org\/10.1111\/obr.13915.","journal-title":"Obes Rev"},{"issue":"3","key":"3741_CR5","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1056\/NEJMoa063988","volume":"356","author":"IS Farooqi","year":"2007","unstructured":"Farooqi IS, Wangensteen T, Collins S, et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med. 2007;356(3):237\u201347. https:\/\/doi.org\/10.1056\/NEJMoa063988.","journal-title":"N Engl J Med"},{"key":"3741_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.689387","volume":"12","author":"N Gregoric","year":"2021","unstructured":"Gregoric N, Groselj U, Bratina N, et al. Two cases with an early presented proopiomelanocortin deficiency\u2014a long-term follow-up and systematic literature review. Front Endocrinol (Lausanne). 2021;12:689387. https:\/\/doi.org\/10.3389\/fendo.2021.689387.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"3741_CR7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/509","volume":"19","author":"H Krude","year":"1998","unstructured":"Krude H, Biebermann H, Luck W, Horn R, Brabant G, Gr\u00fcters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet. 1998;19(2):155\u20137. https:\/\/doi.org\/10.1038\/509.","journal-title":"Nat Genet"},{"issue":"S2","key":"3741_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/dom.15530","volume":"26","author":"CL Roth","year":"2024","unstructured":"Roth CL, McCormack SE. Acquired hypothalamic obesity: a clinical overview and update. Diabetes Obes Metab. 2024;26(S2):34\u201345. https:\/\/doi.org\/10.1111\/dom.15530.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"3741_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02186-z","volume":"17","author":"P K\u00fchnen","year":"2022","unstructured":"K\u00fchnen P, Wabitsch M, von Schnurbein J, et al. Quality of life outcomes in two phase\u00a03 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency. Orphanet J Rare Dis. 2022;17(1):38. https:\/\/doi.org\/10.1186\/s13023-022-02186-z.","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"3741_CR10","doi-asserted-by":"publisher","first-page":"267","DOI":"10.9734\/jammr\/2024\/v36i115637","volume":"36","author":"D Okolo","year":"2024","unstructured":"Okolo D, Akpanumo B, Okeke CH, et al. The influence of obesity on quality of life: a systematic review. J Adv Med Med Res. 2024;36(11):267\u201379. https:\/\/doi.org\/10.9734\/jammr\/2024\/v36i115637.","journal-title":"J Adv Med Med Res"},{"issue":"4","key":"3741_CR11","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1002\/osp4.652","volume":"9","author":"TA Howell","year":"2023","unstructured":"Howell TA, Matza LS, Mallya UG, Goldstone AP, Butsch WS, Lazarus E. Health state utilities associated with hyperphagia: data for use in cost-utility models. Obes Sci Pract. 2023;9(4):376\u201382. https:\/\/doi.org\/10.1002\/osp4.652.","journal-title":"Obes Sci Pract"},{"issue":"1","key":"3741_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-023-02723-4","volume":"18","author":"E Forsythe","year":"2023","unstructured":"Forsythe E, Mallya UG, Yang M, et al. Burden of hyperphagia and obesity in Bardet\u2013Biedl syndrome: a multicountry survey. Orphanet J Rare Dis. 2023;18(1):182. https:\/\/doi.org\/10.1186\/s13023-023-02723-4.","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"3741_CR13","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1007\/s12325-023-02443-y","volume":"40","author":"C Ervin","year":"2023","unstructured":"Ervin C, Norcross L, Mallya UG, et al. Interview-based patient- and caregiver-reported experiences of hunger and improved quality of life with setmelanotide treatment in Bardet\u2013Biedl syndrome. Adv Ther. 2023;40(5):2394\u2013411. https:\/\/doi.org\/10.1007\/s12325-023-02443-y.","journal-title":"Adv Ther"},{"issue":"4","key":"3741_CR14","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1007\/s12325-022-02059-8","volume":"39","author":"M Wabitsch","year":"2022","unstructured":"Wabitsch M, Fehnel S, Mallya UG, et al. Understanding the patient experience of hunger and improved quality of life with setmelanotide treatment in POMC and LEPR deficiencies. Adv Ther. 2022;39(4):1772\u201383. https:\/\/doi.org\/10.1007\/s12325-022-02059-8.","journal-title":"Adv Ther"},{"key":"3741_CR15","unstructured":"FDA. Setmelanotide drug label. 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/213793Orig1s008lbl.pdf. Accessed 20 Jan 2026."},{"key":"3741_CR16","unstructured":"AJMC. FDA approves setmelanotide for adult and pediatric patients with acquired hypothalamic obesity. 2026. https:\/\/www.ajmc.com\/view\/fda-approves-setmelanotide-for-adult-and-pediatric-patients-with-acquired-hypothalamic-obesity. Accessed Mar 20."},{"key":"3741_CR17","unstructured":"Rhythm Pharmaceuticals. Rhythm Pharmaceuticals announces FDA approval of IMCIVREE\u00ae (setmelanotide) for patients with acquired hypothalamic obesity. 2026. https:\/\/ir.rhythmtx.com\/news-releases\/news-release-details\/rhythm-pharmaceuticals-announces-fda-approval-imcivreer-1. Accessed Mar 20."},{"issue":"12","key":"3741_CR18","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/s2213-8587(20)30364-8","volume":"8","author":"K Cl\u00e9ment","year":"2020","unstructured":"Cl\u00e9ment K, van den Akker E, Argente J, Bahm A, Chung WK, Connors H, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase\u00a03 trials. Lancet Diabetes Endocrinol. 2020;8(12):960\u201370. https:\/\/doi.org\/10.1016\/s2213-8587(20)30364-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"3741_CR19","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/s2213-8587(22)00277-7","volume":"10","author":"AM Haqq","year":"2022","unstructured":"Haqq AM, Chung WK, Dollfus H, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet\u2013Biedl syndrome and Alstr\u00f6m syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase\u00a03 trial with an open-label period. Lancet Diabetes Endocrinol. 2022;10(12):859\u201368. https:\/\/doi.org\/10.1016\/s2213-8587(22)00277-7.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3741_CR20","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf149.074","author":"SA Phillips","year":"2025","unstructured":"Phillips SA, van Santen HM, Hamilton JK, et al. Efficacy and safety of setmelanotide in acquired hypothalamic obesity: results from a double-blind, multicenter, placebo-controlled, randomized phase\u00a03 trial. J Endocr Soc. 2025. https:\/\/doi.org\/10.1210\/jendso\/bvaf149.074.","journal-title":"J Endocr Soc"},{"issue":"7","key":"3741_CR21","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/oby.24287","volume":"33","author":"MJ Abuzzahab","year":"2025","unstructured":"Abuzzahab MJ, Dubern B, Goldstone AP, et al. Improving the diagnosis of hyperphagia in melanocortin-4 receptor pathway diseases. Obesity. 2025;33(7):1217\u201331. https:\/\/doi.org\/10.1002\/oby.24287.","journal-title":"Obesity"},{"issue":"1","key":"3741_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-020-00259-w","volume":"4","author":"J Fastenau","year":"2020","unstructured":"Fastenau J, Rozjabek H, Qin S, et al. Psychometric evaluation of the DAILY EATS questionnaire in individuals living with obesity. J Patient Rep Outcomes. 2020;4(1):99. https:\/\/doi.org\/10.1186\/s41687-020-00259-w.","journal-title":"J Patient Rep Outcomes"},{"key":"3741_CR23","unstructured":"FDA. Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments. 2025. https:\/\/www.fda.gov\/media\/159500\/download. Accessed Mar 16."},{"key":"3741_CR24","unstructured":"FDA. Patient-focused drug development guidance public workshop: methods to identify what is important to patients & select, develop or modify fit-for-purpose clinical outcomes assessments. 2018. https:\/\/www.fda.gov\/media\/116277\/download. Accessed Mar 16."},{"key":"3741_CR25","unstructured":"FDA. Patient-focused drug development: methods to identify what is important to patients. 2022. https:\/\/www.fda.gov\/media\/131230\/download. Accessed Mar 16."},{"issue":"1","key":"3741_CR26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1037\/1082-989X.1.1.30","volume":"1","author":"KO McGraw","year":"1996","unstructured":"McGraw KO, Wong SP. Forming inferences about some intraclass correlation coefficients. Psychol Methods. 1996;1(1):30\u201346. https:\/\/doi.org\/10.1037\/1082-989X.1.1.30.","journal-title":"Psychol Methods"},{"issue":"4","key":"3741_CR27","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1007\/s11136-018-2076-0","volume":"28","author":"S Qin","year":"2019","unstructured":"Qin S, Nelson L, McLeod L, Eremenco S, Coons SJ. Assessing test-retest reliability of patient-reported outcome measures using intraclass correlation coefficients: recommendations for selecting and documenting the analytical formula. Qual Life Res. 2019;28(4):1029\u201333. https:\/\/doi.org\/10.1007\/s11136-018-2076-0.","journal-title":"Qual Life Res"},{"key":"3741_CR28","volume-title":"Psychometric theory","author":"J Nunnally","year":"1994","unstructured":"Nunnally J, Bernstein L. Psychometric theory. New York: McGraw-Hill ; 1994."},{"issue":"1","key":"3741_CR29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","volume":"112","author":"JA Cohen","year":"1992","unstructured":"Cohen JA. A power primer. Psychol Bull. 1992;112(1):155\u20139. https:\/\/doi.org\/10.1037\/0033-2909.112.1.155.","journal-title":"Psychol Bull"},{"key":"3741_CR30","volume-title":"Applied statistics for the behavioral sciences","author":"DE Hinkle","year":"2002","unstructured":"Hinkle DE, Wiersma W, Jurs SG. Applied statistics for the behavioral sciences. 5th ed. Boston: Houghton Mifflin; 2002.","edition":"5th ed"},{"issue":"1","key":"3741_CR31","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1081\/copd-200050663","volume":"2","author":"RD Hays","year":"2005","unstructured":"Hays RD, Farivar SS, Liu H. Approaches and recommendations for estimating minimally important differences for health-related quality of life measures. COPD. 2005;2(1):63\u20137. https:\/\/doi.org\/10.1081\/copd-200050663.","journal-title":"COPD"},{"issue":"2","key":"3741_CR32","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","volume":"61","author":"D Revicki","year":"2008","unstructured":"Revicki D, Hays RD, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol. 2008;61(2):102\u20139. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.03.012.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"3741_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11136-013-0443-4","volume":"23","author":"PM Fayers","year":"2014","unstructured":"Fayers PM, Hays RD. Don\u2019t middle your MIDs: regression to the mean shrinks estimates of minimally important differences. Qual Life Res. 2014;23(1):1\u20134. https:\/\/doi.org\/10.1007\/s11136-013-0443-4.","journal-title":"Qual Life Res"},{"key":"3741_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198527695.003.0003","volume-title":"Assessing quality of life in clinical trials: methods and practice","author":"RD Hays","year":"2005","unstructured":"Hays RD, Revicki D. Reliability and validity (including responsiveness). In: Fayers P, Hays R, editors. Assessing quality of life in clinical trials: methods and practice. Oxford University Press; 2005. https:\/\/doi.org\/10.1093\/oso\/9780198527695.003.0003."},{"key":"3741_CR35","unstructured":"Roth CL, Phillips SA, McCormack SE, et al. Experiences and observations with acquired hypothalamic obesity: a qualitative interview substudy. In: Presented at the endocrine society; 12\u201315 July 2025. San Francisco."},{"key":"3741_CR36","unstructured":"Roth CL, Phillips SA, McCormack SE, et al. Patient- and caregiver-reported experience with acquired hypothalamic obesity in the TRANSCEND trial. In: Presented at the obesity week; 4\u20137 November 2025. Atlanta."},{"issue":"1","key":"3741_CR37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/2168479018772569","volume":"53","author":"E Richardson","year":"2019","unstructured":"Richardson E, Burnell J, Adams HR, et al. Developing and implementing performance outcome assessments: evidentiary, methodologic, and operational considerations. Ther Innov Regul Sci. 2019;53(1):146\u201353. https:\/\/doi.org\/10.1177\/2168479018772569.","journal-title":"Ther Innov Regul Sci"},{"key":"3741_CR38","unstructured":"FDA. Patient-reported outcome measures: use in medical product development to support labeling claims. 2009. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-reported-outcome-measures-use-medical-product-development-support-labeling-claims. Accessed Feb 2026."},{"key":"3741_CR39","unstructured":"ClinicalTrials.gov. A phase\u00a03, double blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of setmelanotide in patients with acquired hypothalamic obesity. 2023."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03741-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03741-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03741-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:28:23Z","timestamp":1790839703000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03741-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":39,"alternative-id":["3741"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03741-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"30 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Claire Ervin, Lindsey Norcross, and Sakshi Bhargava are full-time employees of RTI Health Solutions, a subsidiary of RTI International, which was retained by Rhythm Pharmaceuticals, Inc., to conduct the research that is the subject of this manuscript. Their compensation is unconnected to the studies on which they work. Usha G. Mallya is an employee of Rhythm Pharmaceuticals, Inc., and may hold shares and\/or stock options in the company. Karine Cl\u00e9ment is a primary investigator for Rhythm Pharmaceuticals, Inc., and her research group has received research support from Rhythm Pharmaceuticals, Inc. Christian L. Roth has received compensation for consulting, advisory board participation, and speaking engagements from Rhythm Pharmaceuticals, Inc., compensation for consulting from Saniona, and his institution has received research support from Rhythm Pharmaceuticals, Inc. Peter K\u00fchnen has participated on a safety board, and their institution has received funding for clinical trial research from Rhythm Pharmaceuticals, Inc. Andrea M. Haqq served on an advisory board for Rhythm Pharmaceuticals, Inc., Pfizer, and is a principal investigator for clinical trials with Rhythm Pharmaceuticals, Inc., Acadia Pharmaceuticals, Eli Lilly, Novo Nordisk, and Aardvark Therapeutics. Jes\u00fas Argente received compensation for lectures and the BBS advisory board from Rhythm Pharmaceuticals, Inc. Jennifer L. Miller has received study funding from Rhythm Pharmaceuticals, Inc., Soleno Therapeutics, and Harmony Biosciences.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained for participation in the clinical trials of setmelanotide (NCT03287960, NCT02896192, NCT03746522, and NCT05774756); the trials were conducted in accordance with International Council on Harmonisation for Good Clinical Practice and the Declaration of Helsinki with institutional review board or independent ethics committee approval obtained at all trial sites. For the qualitative interviews, study site staff obtained written informed consent for interview participation and for participant contact information to be provided to RTI Health Solutions for scheduling and conducting interviews. The informed consent forms notified participants that their responses would be audio recorded and fully transcribed, with the potential that their response could be published in a journal without attribution. Verbal consent also was obtained prior to recording interviews. All patients provided informed consent for data to be reported in aggregate and anonymously. RTI International\u2019s institutional review board approved the qualitative interview studies for patients with BBS (STUDY00021489) and acquired HO (STUDY00022362). The LEPR and POMC qualitative interview study was deemed exempt from review by RTI International\u2019s institutional review board.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}